ArticleScientific reports2025
Exploring hypoxia driven subtypes of pulmonary arterial hypertension through transcriptomics single cell sequencing and machine learning.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Broiler Ascites Syndrome as a Potential Spontaneous Animal Model for Human Pulmonary Arterial Hypertension: A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Sex-specific omics scores of sex hormones and associations with metabolic and sleep disorders.medRxiv : the preprint server for health sciences · 2026Article
- Mechanistic studies of molecular networks associated with pulmonary hypertension explored by combined transcriptome analysis of Project-methylation.Clinical epigenetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) is a progressive cardiovascular disease characterized by elevated pulmonary arterial pressure, leading to right heart failure and death. Despite advancements in diagnosis and treatment, it remains incurable, and its mechanisms are poorly understood. This study aimed to integrate multi-omics data analysis and machine learning techniques to uncover the molecular characteristics and subtypes of PAH, providing insights into precise diagnosis and therapeutic strategies. We employed consensus clustering to classify PAH patients into subgroups based on multi-omics data. Differential expression and enrichment analyses were conducted to identify key genes and pathways. Machine learning models were developed to predict PAH subtypes and assess their diagnostic performance. PAH patients were divided into two subgroups: C1 and C2. The C2 subgroup showed significantly upregulated hypoxia-related genes, indicating distinct pathogenic mechanisms. Key genes associated with hypoxia, immune regulation, and inflammation were identified, alongside enriched pathways such as TNF, IL-17, and HIF-1 in the C2 subgroup. Machine learning models achieved high accuracy (AUC > 0.85) in distinguishing hypoxia-associated subtypes, supporting their utility for precise diagnosis. Potential therapeutic targets were identified in the TNF and HIF-1 pathways. This study provides novel insights into PAH's molecular subtypes and their distinct mechanisms, offering diagnostic tools and potential therapeutic targets for personalized treatment. Validation in larger cohorts and experimental studies is essential to confirm the identified biomarkers and pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.